During a trial centering on Johnson & Johnson’s ASR hip implants, Bloomberg reports, a biomedical engineering expert told the jury that the devices had multiple design flaws.
Johnson & Johnson recalled the all-metal implants, manufactured by subsidiary DePuy Orthopaedics, in 2010. At the time, the company said 12 percent fail within five years. Subsequent studies found that nearly half of them ...
continue reading...
A piece in The Economist deals with the negative information coming out in Johnson & Johnson’s trial over ASR hip implants manufactured by its subsidiary, DePuy Orthopaedics.
“Most companies do everything they can to keep their executives away from court,” the piece states. “A case in California helps to demonstrate why.”
Studies have shown nearly half of the implants break down and ...
continue reading...
In a bipartisan effort, U.S. Senators have reintroduced legislation banning a pharmaceutical industry practice that keeps lower-cost medications away from patients who need them. The practice, commonly called “pay for delay,” occurs when one drug company pays another to delay introducing a less-expensive generic version of a medication.
According to Reuters, both American and European anti-trust regulators have long criticized the practice. It recently came to the forefront again after European ...
continue reading...
In a Los Angeles Superior Court trial, an occupational medicine specialist testified that a man’s artificial hip had to be removed because of “toxic exposure” from metal debris that the implant was shedding, according to a Reuters story.
Plaintiff Loren Kransky’s is the first of more than 10,000 U.S. lawsuits about the implants to go to trial.
The artificial hips, made by Johnson & Johnson subsidiary DePuy Orthopedics, feature both a ball ...
continue reading...
European regulators are accusing Johnson & Johnson of illegally paying another company to delay the availability of a generic version of a product – in the process denying cancer patients access to a less expensive source of a drug that eases severe pain.
According to a story in the New York Times, the product at issue is a transdermal patch used to deliver the drug fentanyl through the skin. Antitrust authorities ...
continue reading...Johnson & Johnson appointed Andrew Ekdahl to head its orthopaedics division in 2011, a year after the company recalled its ASR artificial hip joints following thousands of complaints that they caused debilitating injuries.
According to the New York Times, the company had billed Ekdahl’s appointment as a fresh start.
The Times reports that Ekdahl had supervised the device’s introduction in the United ...
continue reading...
